Serum lipid profiles in patients receiving endocrine treatment for breast cancer-the results from the Celecoxib Anti-Aromatase Neoadjuvant (CAAN) Trial

The initial results show that different neoadjuvant anti-aromatase therapies has similar efficacy but the combination with celecoxib may have an advantageous effects on the serum lipid profiles.